Shorter, simpler breast cancer treatment: where evidence meets practice, PgII.

Key Highlights:

• Vrinda Thakker, diagnosed with metastatic HER2-positive breast cancer in December 2021, shifted from intravenous to subcutaneous targeted therapy [trastuzumab and pertuzumab].
• Subcutaneous injections take only 2-3 minutes, replacing the previous hours-long intravenous sessions, reducing hospital time and risks like infections.
• Clinical trials like HannaH and FeDeriCa confirm that subcutaneous trastuzumab matches intravenous infusion in safety, efficacy, and drug absorption.
• The ADEPT trial showed subcutaneous dosing cut treatment chair time by about an hour and pharmacy preparation time by over an hour.
• A fixed-dose combination of pertuzumab and trastuzumab, marketed as PHESGO, delivers both antibodies in a single subcutaneous injection.

Detailed Insights:

• HER2-positive breast cancer treatment has shifted towards subcutaneous delivery to reduce hospital time while maintaining therapeutic outcomes.
• Recombinant human hyaluronidase (rHuPH20) is used in subcutaneous formulations to temporarily break down hyaluronan, allowing absorption of large molecules through the skin.
• The first real-world report on PHESGO in India showed similar outcomes across early and metastatic disease, with most patients preferring the subcutaneous route.
• Shorter treatment times benefit patients, especially daily-wage earners and elderly caregivers, by reducing the time commitment from travel, waiting, and the procedure itself.
• Hospitals benefit from streamlined patient flow, managing more cases efficiently without crowding infusion units due to reduced loading and preparation time with subcutaneous delivery.
• Access to subcutaneous therapy remains uneven across India due to variations in facilities, staff training, and inclusion in government oncology programs.
• Oncologists note that shorter treatment modes improve patient experience by reducing physical and emotional strain associated with long hospital stays.
• Besides shorter treatments, measures like scalp cooling devices and precision surgery are used to make the treatment process less intrusive and more comfortable.

Scientific/Technical Concepts Involved:

• HER2-positive breast cancer: A type of breast cancer where the cells have too much of the HER2 protein, promoting cancer cell growth.
• Trastuzumab: A monoclonal antibody that targets the HER2 receptor, used in treating HER2-positive breast cancer.
• Pertuzumab: An antibody used in combination with trastuzumab for HER2-positive breast cancer, enhancing the effects of trastuzumab.
• Recombinant human hyaluronidase (rHuPH20): An enzyme that temporarily breaks down hyaluronan in the tissue, facilitating absorption of large molecules through the skin.